Kenneth Duchin1, Giorgio Senaldi1, Vance Warren1, Thomas Marbury2, Kenneth Lasseter3, Hamim Zahir4. 1. Daiichi Sankyo, Inc., 211 Mount Airy Road, Basking Ridge, NJ, USA. 2. Orlando Clinical Research Center, Orlando, FL, USA. 3. Clinical Pharmacology of Miami, Inc., Hialeah, FL, USA. 4. Daiichi Sankyo, Inc., 211 Mount Airy Road, Basking Ridge, NJ, USA. hzahir@dsi.com.
Abstract
BACKGROUND AND OBJECTIVES: Mirogabalin is an α2δ ligand being developed to treat neuropathic pain. A small fraction of mirogabalin is metabolized by the liver, where hepatic impairment may affect exposure. The objective of this phase I, open-label single-dose study was to determine if mild or moderate hepatic impairment alters the pharmacokinetics of mirogabalin. METHODS: Serial blood samples were collected for determination of maximum observed concentration, time to maximum concentration, and area under the concentration-time curve until the last quantifiable concentration of the active free form (A200-700) and inactive lactam metabolite (A204-4455) of mirogabalin. RESULTS: The A200-700 maximum observed concentration was similar in subjects with mild hepatic impairment but lower in subjects with moderate hepatic impairment vs. control subjects. The A204-4455 maximum observed concentration was lower in subjects with mild and moderate hepatic impairment vs. control groups. The A200-700 area under the concentration-time curve until the last quantifiable concentration was slightly lower in subjects with mild hepatic impairment and slightly higher in subjects with moderate hepatic impairment vs. control subjects. Peak A204-4455 levels were approximately 22% and 31% lower for subjects with mild and moderate hepatic impairment vs. control individuals, respectively. Exposure to A204-4455 was approximately 37% lower in subjects with mild hepatic impairment but unaffected in subjects with moderate hepatic impairment vs. control groups. Two subjects in the mild hepatic impairment group reported a treatment-emergent adverse event of mild somnolence. No serious or severe treatment-emergent adverse events, discontinuations as a result of treatment-emergent adverse events, or deaths were reported. CONCLUSIONS: Mild hepatic impairment resulted in lower A200-700 and A204-4455 exposure, while moderate hepatic impairment did not affect A200-700 exposure. Overall, mild-to-moderate hepatic impairment did not have a significant effect on mirogabalin exposure. A single 15-mg dose of mirogabalin was well tolerated by subjects with mild or moderate hepatic impairment.
BACKGROUND AND OBJECTIVES:Mirogabalin is an α2δ ligand being developed to treat neuropathic pain. A small fraction of mirogabalin is metabolized by the liver, where hepatic impairment may affect exposure. The objective of this phase I, open-label single-dose study was to determine if mild or moderate hepatic impairment alters the pharmacokinetics of mirogabalin. METHODS: Serial blood samples were collected for determination of maximum observed concentration, time to maximum concentration, and area under the concentration-time curve until the last quantifiable concentration of the active free form (A200-700) and inactive lactam metabolite (A204-4455) of mirogabalin. RESULTS: The A200-700 maximum observed concentration was similar in subjects with mild hepatic impairment but lower in subjects with moderate hepatic impairment vs. control subjects. The A204-4455 maximum observed concentration was lower in subjects with mild and moderate hepatic impairment vs. control groups. The A200-700 area under the concentration-time curve until the last quantifiable concentration was slightly lower in subjects with mild hepatic impairment and slightly higher in subjects with moderate hepatic impairment vs. control subjects. Peak A204-4455 levels were approximately 22% and 31% lower for subjects with mild and moderate hepatic impairment vs. control individuals, respectively. Exposure to A204-4455 was approximately 37% lower in subjects with mild hepatic impairment but unaffected in subjects with moderate hepatic impairment vs. control groups. Two subjects in the mild hepatic impairment group reported a treatment-emergent adverse event of mild somnolence. No serious or severe treatment-emergent adverse events, discontinuations as a result of treatment-emergent adverse events, or deaths were reported. CONCLUSIONS: Mild hepatic impairment resulted in lower A200-700 and A204-4455 exposure, while moderate hepatic impairment did not affect A200-700 exposure. Overall, mild-to-moderate hepatic impairment did not have a significant effect on mirogabalin exposure. A single 15-mg dose of mirogabalin was well tolerated by subjects with mild or moderate hepatic impairment.
Authors: Chun-Ying Li; Xiu-Lin Zhang; Elizabeth A Matthews; Kang-Wu Li; Ambereen Kurwa; Amin Boroujerdi; Jimmy Gross; Michael S Gold; Anthony H Dickenson; Guoping Feng; Z David Luo Journal: Pain Date: 2006-06-09 Impact factor: 6.961
Authors: Claudia S Bauer; Manuela Nieto-Rostro; Wahida Rahman; Alexandra Tran-Van-Minh; Laurent Ferron; Leon Douglas; Ivan Kadurin; Yorain Sri Ranjan; Laura Fernandez-Alacid; Neil S Millar; Anthony H Dickenson; Rafael Lujan; Annette C Dolphin Journal: J Neurosci Date: 2009-04-01 Impact factor: 6.167
Authors: Robert H Dworkin; Dennis C Turk; Kathleen W Wyrwich; Dorcas Beaton; Charles S Cleeland; John T Farrar; Jennifer A Haythornthwaite; Mark P Jensen; Robert D Kerns; Deborah N Ader; Nancy Brandenburg; Laurie B Burke; David Cella; Julie Chandler; Penny Cowan; Rozalina Dimitrova; Raymond Dionne; Sharon Hertz; Alejandro R Jadad; Nathaniel P Katz; Henrik Kehlet; Lynn D Kramer; Donald C Manning; Cynthia McCormick; Michael P McDermott; Henry J McQuay; Sanjay Patel; Linda Porter; Steve Quessy; Bob A Rappaport; Christine Rauschkolb; Dennis A Revicki; Margaret Rothman; Kenneth E Schmader; Brett R Stacey; Joseph W Stauffer; Thorsten von Stein; Richard E White; James Witter; Stojan Zavisic Journal: J Pain Date: 2007-12-11 Impact factor: 5.820
Authors: Mark J Field; Peter J Cox; Emma Stott; Heather Melrose; James Offord; Ti-Zhi Su; Steve Bramwell; Laura Corradini; Steven England; Joanna Winks; Ross A Kinloch; Jan Hendrich; Annette C Dolphin; Tony Webb; Dic Williams Journal: Proc Natl Acad Sci U S A Date: 2006-11-06 Impact factor: 11.205
Authors: Nanna B Finnerup; Nadine Attal; Simon Haroutounian; Ewan McNicol; Ralf Baron; Robert H Dworkin; Ian Gilron; Maija Haanpää; Per Hansson; Troels S Jensen; Peter R Kamerman; Karen Lund; Andrew Moore; Srinivasa N Raja; Andrew S C Rice; Michael Rowbotham; Emily Sena; Philip Siddall; Blair H Smith; Mark Wallace Journal: Lancet Neurol Date: 2015-01-07 Impact factor: 44.182
Authors: Eric Y Chen; Sascha S Beutler; Alan D Kaye; Amber N Edinoff; Seyed-Hossein Khademi; Andrea E Stoltz; Nicole R Rueb; Elyse M Cornett; Winston J Suh Journal: Anesth Pain Med Date: 2021-12-22